Journal
CANCER DISCOVERY
Volume 3, Issue 9, Pages 971-974Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/2159-8290.CD-13-0405
Keywords
-
Categories
Funding
- NCI NIH HHS [P30 CA006973] Funding Source: Medline
Ask authors/readers for more resources
The appearance of a mutant androgen receptor, AR(F876L), in prostate cancer cells chronically exposed to enzalutamide or ARN-509 promotes a switch from antagonist to agonist receptor function, undermining the potential long-term effectiveness of these second-generation antiandrogen drugs. (C) 2013 AACR.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
